R1	Has_temporal Arg1:T1 Arg2:T2	
R2	Has_index Arg1:T2 Arg2:T3	
*	OR T5 T6
R3	Has_value Arg1:T4 Arg2:T8	
R4	Has_qualifier Arg1:T4 Arg2:T5	
R5	Has_value Arg1:T9 Arg2:T10	
R6	Has_value Arg1:T11 Arg2:T12	
*	OR T16 T17
R7	Has_negation Arg1:T19 Arg2:T18	
*	OR T20 T21
*	OR T22 T23
R8	Subsumes Arg1:T21 Arg2:T22	
*	OR T25 T26 T27 T28 T29
*	OR T32 T33
R9	Has_value Arg1:T35 Arg2:T34	
T1	Procedure 13 20	vaccine
T2	Temporal 21 58	within a month prior to study vaccine
T3	Reference_point 45 58	study vaccine
T4	Measurement 69 83	serum antibody
T5	Qualifier 92 112	Hep B surface antige
T6	Qualifier 121 144	core Hep B core antigen
T8	Value 60 68	Positive
T9	Measurement 146 149	HIV
T10	Value 150 158	positive
T11	Measurement 164 167	HCV
T12	Value 168 176	negative
T13	Temporal 198 222	History of HCV infection
T14	Competing_trial 254 405	Participation in another clinical study of an investigational product currently or within the past 90 days, or expected participation during this study
T15	Post-eligibility 407 502	In the opinion of the investigator, the volunteer is unlikely to comply with the study protocol
T16	Condition 607 623	immunodeficiency
T17	Condition 627 645	autoimmune disease
T18	Negation 647 661	in addition to
T19	Condition 662 675	HCV infection
T20	Drug 710 727	systemic steroids
T21	Procedure 737 765	immunomodulatory medications
T22	Procedure 776 798	anticancer medications
T23	Procedure 803 824	antiviral medications
T25	Condition 937 945	diabetes
T26	Condition 947 970	coronary artery disease
T27	Condition 972 993	rheumatologic illness
T28	Condition 995 1005	malignancy
T29	Condition 1007 1022	substance abuse
T30	Post-eligibility 1096 1142	Unable to continue participation for 156 weeks
T31	Procedure 1164 1187	Hepatitis B vaccination
T32	Person 1192 1196	Male
T33	Person 1200 1206	female
T34	Value 1207 1226	< 18 and > 62 years
T35	Person 1230 1233	age
T36	Pregnancy_considerations 1235 1259	Is pregnant or lactating
T37	Condition 1272 1293	Hepatitis B infection
T38	Condition 1339 1348	cirrhosis
